Does LAPATINIB DITOSYLATE Cause Malignant neoplasm progression? 183 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 183 reports of Malignant neoplasm progression have been filed in association with LAPATINIB DITOSYLATE (Lapatinib). This represents 4.6% of all adverse event reports for LAPATINIB DITOSYLATE.
183
Reports of Malignant neoplasm progression with LAPATINIB DITOSYLATE
4.6%
of all LAPATINIB DITOSYLATE reports
55
Deaths
47
Hospitalizations
How Dangerous Is Malignant neoplasm progression From LAPATINIB DITOSYLATE?
Of the 183 reports, 55 (30.1%) resulted in death, 47 (25.7%) required hospitalization, and 5 (2.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LAPATINIB DITOSYLATE. However, 183 reports have been filed with the FAERS database.
What Other Side Effects Does LAPATINIB DITOSYLATE Cause?
Diarrhoea (893)
Death (665)
Nausea (317)
Fatigue (301)
Vomiting (259)
Rash (249)
Drug ineffective (183)
Off label use (141)
Disease progression (137)
Palmar-plantar erythrodysaesthesia syndrome (135)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which LAPATINIB DITOSYLATE Alternatives Have Lower Malignant neoplasm progression Risk?
LAPATINIB DITOSYLATE vs LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN
LAPATINIB DITOSYLATE vs LARONIDASE
LAPATINIB DITOSYLATE vs LAROTRECTINIB
LAPATINIB DITOSYLATE vs LASILIX
LAPATINIB DITOSYLATE vs LASIX